Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.15-0.35 (-0.63%)
At close: 04:00PM EDT
55.16 +0.01 (+0.02%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Previous Close55.50
Open54.88
Bid55.17 x 1000
Ask55.50 x 3200
Day's Range54.64 - 55.21
52 Week Range46.93 - 58.10
Volume3,652,672
Avg. Volume2,277,998
Market Cap138.102B
Beta (5Y Monthly)0.36
PE Ratio (TTM)19.47
EPS (TTM)2.83
Earnings DateN/A
Forward Dividend & Yield1.80 (3.24%)
Ex-Dividend DateMay 26, 2022
1y Target Est70.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SNY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sanofi
    Analyst Report: SanofiSanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement